Aravind Asokan

Summary

Affiliation: University of North Carolina
Country: USA

Publications

  1. pmc Reengineered AAV vectors: old dog, new tricks
    Aravind Asokan
    Gene Therapy Center, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
    Discov Med 9:399-403. 2010
  2. pmc Reengineering a receptor footprint of adeno-associated virus enables selective and systemic gene transfer to muscle
    Aravind Asokan
    Gene Therapy Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA
    Nat Biotechnol 28:79-82. 2010
  3. pmc Cytotoxic-T-lymphocyte-mediated elimination of target cells transduced with engineered adeno-associated virus type 2 vector in vivo
    Chengwen Li
    Gene Therapy Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
    J Virol 83:6817-24. 2009
  4. pmc Glycan binding avidity determines the systemic fate of adeno-associated virus type 9
    Shen Shen
    Gene Therapy Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA
    J Virol 86:10408-17. 2012
  5. pmc Single amino acid modification of adeno-associated virus capsid changes transduction and humoral immune profiles
    Chengwen Li
    Gene Therapy Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA
    J Virol 86:7752-9. 2012
  6. pmc Systemic gene transfer to skeletal muscle using reengineered AAV vectors
    Jana L Phillips
    Gene Therapy Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
    Methods Mol Biol 709:141-51. 2011
  7. pmc Engineering and selection of shuffled AAV genomes: a new strategy for producing targeted biological nanoparticles
    Wuping Li
    Gene Therapy Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599 7352, USA
    Mol Ther 16:1252-60. 2008
  8. pmc Production of recombinant adeno-associated viral vectors and use in in vitro and in vivo administration
    Steven J Gray
    University of North Carolina at Chapel Hill, School of Medicine, Chapel Hill, North Carolina, USA
    Curr Protoc Neurosci . 2011
  9. pmc Engineering liver-detargeted AAV9 vectors for cardiac and musculoskeletal gene transfer
    Nagesh Pulicherla
    Gene Therapy Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA
    Mol Ther 19:1070-8. 2011
  10. pmc Single amino acid changes can influence titer, heparin binding, and tissue tropism in different adeno-associated virus serotypes
    Zhijian Wu
    Gene Therapy Center, 7113 Thurston Building, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599 7352, USA
    J Virol 80:11393-7. 2006

Collaborators

Detail Information

Publications25

  1. pmc Reengineered AAV vectors: old dog, new tricks
    Aravind Asokan
    Gene Therapy Center, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
    Discov Med 9:399-403. 2010
    ..Recent approaches driven by the availability of structural information have yielded a new generation of reengineered AAV vectors...
  2. pmc Reengineering a receptor footprint of adeno-associated virus enables selective and systemic gene transfer to muscle
    Aravind Asokan
    Gene Therapy Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA
    Nat Biotechnol 28:79-82. 2010
    ..These features of AAV2i8 suggest that it is well suited to translational studies in gene therapy of musculoskeletal disorders...
  3. pmc Cytotoxic-T-lymphocyte-mediated elimination of target cells transduced with engineered adeno-associated virus type 2 vector in vivo
    Chengwen Li
    Gene Therapy Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
    J Virol 83:6817-24. 2009
    ..Notably, this model system can be exploited to study the kinetics of capsid presentation from different serotypes of AAV and permit the design of novel strategies to block CTL-mediated killing of AAV-transduced cells...
  4. pmc Glycan binding avidity determines the systemic fate of adeno-associated virus type 9
    Shen Shen
    Gene Therapy Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA
    J Virol 86:10408-17. 2012
    ....
  5. pmc Single amino acid modification of adeno-associated virus capsid changes transduction and humoral immune profiles
    Chengwen Li
    Gene Therapy Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA
    J Virol 86:7752-9. 2012
    ..Our results suggest that AAV types can be utilized not only as templates to generate mutants with enhanced transduction efficiency but also as substrates for repeat administration...
  6. pmc Systemic gene transfer to skeletal muscle using reengineered AAV vectors
    Jana L Phillips
    Gene Therapy Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
    Methods Mol Biol 709:141-51. 2011
    ..Methods to evaluate the efficiency of gene transfer to skeletal muscle following intravenous or isolated limb infusion of AAV -vectors in mice are discussed in detail...
  7. pmc Engineering and selection of shuffled AAV genomes: a new strategy for producing targeted biological nanoparticles
    Wuping Li
    Gene Therapy Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599 7352, USA
    Mol Ther 16:1252-60. 2008
    ..Application of this technology to alternative cell/tissue types using AAV or other viral capsid sequences is likely to yield a new class of biological nanoparticles as vectors for human gene transfer...
  8. pmc Production of recombinant adeno-associated viral vectors and use in in vitro and in vivo administration
    Steven J Gray
    University of North Carolina at Chapel Hill, School of Medicine, Chapel Hill, North Carolina, USA
    Curr Protoc Neurosci . 2011
    ..Two detailed methods are provided for viral vector delivery into the rodent brain and spinal cord, and for histological detection of transgene expression of GFP...
  9. pmc Engineering liver-detargeted AAV9 vectors for cardiac and musculoskeletal gene transfer
    Nagesh Pulicherla
    Gene Therapy Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA
    Mol Ther 19:1070-8. 2011
    ..Liver-detargeted AAV9 variants described herein are excellent candidates for preclinical evaluation in animal models of cardiac and musculoskeletal disease...
  10. pmc Single amino acid changes can influence titer, heparin binding, and tissue tropism in different adeno-associated virus serotypes
    Zhijian Wu
    Gene Therapy Center, 7113 Thurston Building, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599 7352, USA
    J Virol 80:11393-7. 2006
    ....
  11. pmc Adeno-associated virus type 2 (AAV2) capsid-specific cytotoxic T lymphocytes eliminate only vector-transduced cells coexpressing the AAV2 capsid in vivo
    Chengwen Li
    Gene Therapy Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
    J Virol 81:7540-7. 2007
    ..In addition, our data suggest that the mouse model may not mimic the immune response noted in humans and additional modification to AAV vectors may be required for further study in order to elicit a similar cellular immune response...
  12. pmc Surface loop dynamics in adeno-associated virus capsid assembly
    Nina DiPrimio
    Gene Therapy Center, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599 7352, USA
    J Virol 82:5178-89. 2008
    ....
  13. pmc Cellular immune response to cryptic epitopes during therapeutic gene transfer
    Chengwen Li
    Gene Therapy Center, University of North Carolina, Chapel Hill, NC 27599, USA
    Proc Natl Acad Sci U S A 106:10770-4. 2009
    ..Such unforeseen epitope generation warrants careful analysis of transgene sequences for ARFs to reduce the potential for adverse events arising from immune responses during clinical gene therapy protocols...
  14. ncbi request reprint Production of recombinant adeno-associated viral vectors
    Vivian W Choi
    University of North Carolina, Chapel Hill, North Carolina, USA
    Curr Protoc Hum Genet . 2007
    ....
  15. pmc The AAV vector toolkit: poised at the clinical crossroads
    Aravind Asokan
    Gene Therapy Center, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599 7352, USA
    Mol Ther 20:699-708. 2012
    ..This review will provide an overview of preclinical studies with the ever-expanding AAV vector portfolio in large animal models and an update on new lead AAV vector candidates poised for clinical translation...
  16. doi request reprint Production of recombinant adeno-associated viral vectors and use for in vitro and in vivo administration
    Vivian W Choi
    University of North Carolina, Chapel Hill, North Carolina, USA
    Curr Protoc Neurosci . 2006
    ..Two detailed methods are provided for viral vector injection into rat brain and for histological detection of transgene expression, including lacZ and GFP...
  17. pmc Tyrosine cross-linking reveals interfacial dynamics in adeno-associated viral capsids during infection
    Eric D Horowitz
    Gene Therapy Center, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA
    ACS Chem Biol 7:1059-66. 2012
    ..These adverse effects caused by tyrosine oxidation support the notion that interfacial dynamics at the AAV capsid two-fold symmetry axis play a role in externalization of VP N-termini during infection...
  18. pmc Intra- and inter-subunit disulfide bond formation is nonessential in adeno-associated viral capsids
    Nagesh Pulicherla
    Gene Therapy Center, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America
    PLoS ONE 7:e32163. 2012
    ..These studies represent an important step towards understanding the role of inter-subunit interactions that drive AAV capsid assembly...
  19. pmc Terminal N-linked galactose is the primary receptor for adeno-associated virus 9
    Shen Shen
    Gene Therapy Center, University of North Carolina, Chapel Hill, North Carolina 27599, USA
    J Biol Chem 286:13532-40. 2011
    ..Taken together, the studies described herein provide a molecular basis for low infectivity of AAV9 in vitro and a biochemical strategy to enhance gene transfer by AAV9 vectors in general...
  20. pmc An emerging adeno-associated viral vector pipeline for cardiac gene therapy
    Aravind Asokan
    1 Gene Therapy Center, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27516
    Hum Gene Ther 24:906-13. 2013
    ..The current report provides an overview of cardiotropic AAV, existing gaps in our knowledge, and newly engineered AAV strains that are viable candidates for the cardiac gene therapy clinic...
  21. pmc Biophysical and ultrastructural characterization of adeno-associated virus capsid uncoating and genome release
    Eric D Horowitz
    Gene Therapy Center, University of North Carolina, Chapel Hill, NC, USA
    J Virol 87:2994-3002. 2013
    ..Our work further defines the biophysical mechanisms underlying adeno-associated virus uncoating and genome release...
  22. pmc Glycated AAV vectors: chemical redirection of viral tissue tropism
    Eric D Horowitz
    Gene Therapy Center, Thurston Bowles Building CB7352, University of North Carolina, Chapel Hill, NC 27599 7352, USA
    Bioconjug Chem 22:529-32. 2011
    ..Generation of unnatural amino acid side chains through capsid glycation might serve as an orthogonal strategy to engineer AAV vectors displaying novel tissue tropisms for gene therapy applications...
  23. ncbi request reprint Production of recombinant adeno-associated viral vectors for in vitro and in vivo use
    Vivian W Choi
    University of North Carolina, Chapel Hill, North Carolina, USA
    Curr Protoc Mol Biol . 2007
    ....
  24. pmc Adeno-associated virus type 2 contains an integrin alpha5beta1 binding domain essential for viral cell entry
    Aravind Asokan
    Gene Therapy Center, 7113 Thurston Building, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599 7352, USA
    J Virol 80:8961-9. 2006
    ..The aforementioned results suggest that the internalization of AAV2 in 293 cells might follow a "click-to-fit" mechanism that involves the cooperative binding of heparan sulfate and alpha5beta1 integrin by the AAV2 capsids...
  25. ncbi request reprint Adeno-associated virus serotypes: vector toolkit for human gene therapy
    Zhijian Wu
    Gene Therapy Center, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
    Mol Ther 14:316-27. 2006
    ..Strategies for engineering hybrid AAV vectors derived from AAV serotypes and potential implications of the rapidly expanding AAV vector toolkit are discussed...